These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 24260066)

  • 21. Comparison of RECIST, mRECIST, and choi criteria for early response evaluation of hepatocellular carcinoma after transarterial chemoembolization using drug-eluting beads.
    Yeo DM; Choi JI; Lee YJ; Park MY; Chun HJ; Lee HG
    J Comput Assist Tomogr; 2014; 38(3):391-7. PubMed ID: 24681857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histogram Analysis of CT Perfusion of Hepatocellular Carcinoma for Predicting Response to Transarterial Radioembolization: Value of Tumor Heterogeneity Assessment.
    Reiner CS; Gordic S; Puippe G; Morsbach F; Wurnig M; Schaefer N; Veit-Haibach P; Pfammatter T; Alkadhi H
    Cardiovasc Intervent Radiol; 2016 Mar; 39(3):400-8. PubMed ID: 26216725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE).
    Prajapati HJ; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
    Ann Oncol; 2013 Apr; 24(4):965-73. PubMed ID: 23223331
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of health-related quality of life after transarterial chemoembolization and transarterial radioembolization in patients with unresectable hepatocellular carcinoma.
    Kirchner T; Marquardt S; Werncke T; Kirstein MM; Brunkhorst T; Wacker F; Vogel A; Rodt T
    Abdom Radiol (NY); 2019 Apr; 44(4):1554-1561. PubMed ID: 30311050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic Value of Liver Biomarkers in Hepatocellular Carcinoma Patients Undergoing Yttrium 90 Transarterial Radioembolization (TARE): A Retrospective Pilot Study.
    Bayona Molano MDP; Kolber M; Barrera JV; Akram MR; Alnablsi MW; Pothini T; Salem R; Singal AG
    Cureus; 2024 Jun; 16(6):e61904. PubMed ID: 38855496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL?
    Zhao Y; Duran R; Bai W; Sahu S; Wang W; Kabus S; Lin M; Han G; Geschwind JF
    Cardiovasc Intervent Radiol; 2018 Mar; 41(3):433-442. PubMed ID: 29086058
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of RECIST and mRECIST criteria as prognostic factors in patients undergoing repeated iodized oil chemoembolization of intermediate stage hepatocellular carcinoma.
    Hyun D; Shin SW; Cho SK; Park KB; Park HS; Choo SW; Do YS; Choo IW; Shin JW; Lim SJ
    Acta Radiol; 2015 Dec; 56(12):1437-45. PubMed ID: 25480473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology.
    Gordic S; Corcuera-Solano I; Stueck A; Besa C; Argiriadi P; Guniganti P; King M; Kihira S; Babb J; Thung S; Taouli B
    J Hepatol; 2017 Dec; 67(6):1213-1221. PubMed ID: 28823713
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transarterial Radioembolization Following Chemoembolization for Unresectable Hepatocellular Carcinoma: Response Based on Apparent Diffusion Coefficient Change is an Independent Predictor for Survival.
    Klompenhouwer EG; Dresen RC; Verslype C; Laenen A; Bonne L; Vandecaveye V; Maleux G
    Cardiovasc Intervent Radiol; 2018 Nov; 41(11):1716-1726. PubMed ID: 29872894
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survival analysis of transarterial radioembolization with yttrium-90 for hepatocellular carcinoma patients with HBV infection.
    She WH; Cheung TT; Yau TC; Chan AC; Chok KS; Chu FS; Liu RK; Poon RT; Chan SC; Fan ST; Lo CM
    Hepatobiliary Surg Nutr; 2014 Aug; 3(4):185-93. PubMed ID: 25202695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Surrogate Imaging Biomarkers of Response of Colorectal Liver Metastases After Salvage Radioembolization Using 90Y-Loaded Resin Microspheres.
    Shady W; Sotirchos VS; Do RK; Pandit-Taskar N; Carrasquillo JA; Gonen M; Sofocleous CT
    AJR Am J Roentgenol; 2016 Sep; 207(3):661-70. PubMed ID: 27384594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
    Jung ES; Kim JH; Yoon EL; Lee HJ; Lee SJ; Suh SJ; Lee BJ; Seo YS; Yim HJ; Seo TS; Lee CH; Yeon JE; Park JJ; Kim JS; Bak YT; Byun KS
    J Hepatol; 2013 Jun; 58(6):1181-7. PubMed ID: 23395691
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response Evaluation and Survival Prediction Following PD-1 Inhibitor in Patients With Advanced Hepatocellular Carcinoma: Comparison of the RECIST 1.1, iRECIST, and mRECIST Criteria.
    Zhou M; Zhang C; Nie J; Sun Y; Xu Y; Wu F; Huang Y; Li S; Wang Y; Zhou Y; Zheng T
    Front Oncol; 2021; 11():764189. PubMed ID: 34956885
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy.
    Bonekamp S; Halappa VG; Geschwind JF; Li Z; Corona-Villalobos CP; Reyes D; Bhagat N; Cosgrove DP; Pawlik TM; Mezey E; Eng J; Kamel IR
    Radiology; 2013 Aug; 268(2):431-9. PubMed ID: 23616632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transarterial Radioembolization of Hepatocellular Carcinoma, Liver-Dominant Hepatic Colorectal Cancer Metastases, and Cholangiocarcinoma Using Yttrium90 Microspheres: Eight-Year Single-Center Real-Life Experience.
    Pellegrinelli J; Chevallier O; Manfredi S; Dygai-Cochet I; Tabouret-Viaud C; Nodari G; Ghiringhelli F; Riedinger JM; Popoff R; Vrigneaud JM; Cochet A; Aho S; Latournerie M; Loffroy R
    Diagnostics (Basel); 2021 Jan; 11(1):. PubMed ID: 33466706
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602.
    Sato Y; Watanabe H; Sone M; Onaya H; Sakamoto N; Osuga K; Takahashi M; Arai Y;
    Ups J Med Sci; 2013 Mar; 118(1):16-22. PubMed ID: 23167460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adapted Choi response criteria for prediction of clinical outcome in locally advanced gastric cancer patients following preoperative chemotherapy.
    Liu K; Li G; Fan C; Zhou C; Li J
    Acta Radiol; 2012 Mar; 53(2):127-34. PubMed ID: 22156007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatocellular Carcinoma Tumor Dose Response After
    Kappadath SC; Mikell J; Balagopal A; Baladandayuthapani V; Kaseb A; Mahvash A
    Int J Radiat Oncol Biol Phys; 2018 Oct; 102(2):451-461. PubMed ID: 30191875
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic ability of inflammation-based markers in radioembolization for hepatocellular carcinoma.
    Yoneoka G; Bozhilov K; Wong LL
    Hepatoma Res; 2020; 6():. PubMed ID: 33134551
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Initial response to sorafenib by using enhancement criteria in patients with hepatocellular carcinoma.
    Ogasawara S; Kanai F; Ooka Y; Motoyama T; Suzuki E; Tawada A; Chiba T; Yokosuka O
    Hepatol Int; 2013 Jun; 7(2):703-13. PubMed ID: 26201804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.